Q1 EPS Estimates for Simulations Plus Cut by William Blair

Simulations Plus, Inc. (NASDAQ:SLP) – Equities research analysts at William Blair decreased their Q1 2026 EPS estimates for shares of Simulations Plus in a research note issued on Monday, January 27th. William Blair analyst M. Smock now forecasts that the technology company will post earnings per share of $0.16 for the quarter, down from their prior forecast of $0.17. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Simulations Plus’ current full-year earnings is $1.09 per share. William Blair also issued estimates for Simulations Plus’ Q2 2026 earnings at $0.31 EPS, Q4 2026 earnings at $0.41 EPS and FY2026 earnings at $1.32 EPS.

A number of other research analysts also recently weighed in on SLP. BTIG Research cut their price objective on Simulations Plus from $60.00 to $50.00 and set a “buy” rating on the stock in a research note on Thursday, October 24th. KeyCorp lifted their price objective on Simulations Plus from $35.00 to $37.00 and gave the stock an “overweight” rating in a research note on Friday, January 24th. StockNews.com downgraded Simulations Plus from a “hold” rating to a “sell” rating in a research note on Monday, November 4th. Finally, Stephens started coverage on Simulations Plus in a research report on Friday, November 15th. They issued an “overweight” rating and a $39.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $49.40.

Simulations Plus Trading Down 0.6 %

Shares of NASDAQ SLP opened at $33.80 on Wednesday. Simulations Plus has a twelve month low of $24.00 and a twelve month high of $51.22. The firm has a 50-day moving average of $30.19 and a two-hundred day moving average of $32.70. The company has a market capitalization of $679.04 million, a price-to-earnings ratio of 84.50 and a beta of 0.80.

Insiders Place Their Bets

In other news, Director Walter S. Woltosz sold 20,000 shares of Simulations Plus stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $31.76, for a total value of $635,200.00. Following the completion of the transaction, the director now owns 3,442,584 shares in the company, valued at $109,336,467.84. This trade represents a 0.58 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 19.40% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SLP. First Horizon Advisors Inc. boosted its stake in shares of Simulations Plus by 82.6% during the third quarter. First Horizon Advisors Inc. now owns 818 shares of the technology company’s stock valued at $26,000 after purchasing an additional 370 shares during the period. nVerses Capital LLC increased its position in shares of Simulations Plus by 1,100.0% in the third quarter. nVerses Capital LLC now owns 1,200 shares of the technology company’s stock valued at $38,000 after acquiring an additional 1,100 shares during the period. Quantbot Technologies LP purchased a new position in Simulations Plus during the 3rd quarter valued at about $59,000. US Bancorp DE grew its position in shares of Simulations Plus by 37.0% in the 3rd quarter. US Bancorp DE now owns 4,974 shares of the technology company’s stock worth $159,000 after buying an additional 1,343 shares during the last quarter. Finally, Pitcairn Co. raised its holdings in shares of Simulations Plus by 9.1% during the third quarter. Pitcairn Co. now owns 6,599 shares of the technology company’s stock valued at $211,000 after acquiring an additional 549 shares in the last quarter. 78.08% of the stock is currently owned by hedge funds and other institutional investors.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.